Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 6/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 8/20 | 0.56 |
| ▸ | MME | P08473 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281910 | 1.00 | AGTR2 (0.60) | AGTR2AGTR1MME | |
| SCHEMBL2280181 | 0.96 | AGTR2 (0.59) | AGTR2AGTR1MME | |
| SCHEMBL2280168 | 0.96 | AGTR2 (0.59) | AGTR2AGTR1MME | |
| SCHEMBL1457872 | 0.93 | MME (0.66) | AGTR2AGTR1MME | |
| SCHEMBL1458516 | 0.93 | AGTR2 (0.62) | AGTR2AGTR1MME | |
| SCHEMBL1458511 | 0.93 | AGTR2 (0.62) | AGTR2AGTR1MME | |
| SCHEMBL1459474 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1MME | |
| SCHEMBL1459466 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1MME | |
| SCHEMBL1457863 | 0.89 | MME (0.64) | AGTR2AGTR1MME | |
| SCHEMBL1458455 | 0.89 | MME (0.63) | AGTR2AGTR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885MME 5/4885 |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885MME 5/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885MME 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.